Literature DB >> 18664546

Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.

P A Merkel1, D D Cuthbertson, B Hellmich, G S Hoffman, D R W Jayne, C G M Kallenberg, J P Krischer, R Luqmani, A D Mahr, E L Matteson, U Specks, J H Stone.   

Abstract

AIM: Currently, several different instruments are used to measure disease activity and extent in clinical trials of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, leading to division among investigative groups and difficulty comparing study results. An exercise comparing six different vasculitis instruments was performed.
METHODS: A total of 10 experienced vasculitis investigators from 5 countries scored 20 cases in the literature of Wegener granulomatosis or microscopic polyangiitis using 6 disease assessment tools: the Birmingham Vasculitis Activity Score (BVAS), The BVAS for Wegener granulomatosis (BVAS/WG), BVAS 2003, a Physician Global Assessment (PGA), the Disease Extent Index (DEI) and the Five Factor Score (FFS). Five cases were rescored by all raters.
RESULTS: Reliability of the measures was extremely high (intraclass correlations for the six measures all = 0.98). Within each instrument, there were no significant differences or outliers among the scores from the 10 investigators. Test/retest reliability was high for each measure: range = 0.77 to 0.95. The scores of the five acute activity measures correlated extremely well with one another.
CONCLUSIONS: Currently available tools for measuring disease extent and activity in ANCA-associated vasculitis are highly correlated and reliable. These results provide investigators with confidence to compare different clinical trial data and helps form common ground as international research groups develop new, improved and universally accepted vasculitis disease assessment instruments.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18664546      PMCID: PMC3139244          DOI: 10.1136/ard.2008.097758

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

1.  A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).

Authors:  J H Stone; G S Hoffman; P A Merkel; Y I Min; M L Uhlfelder; D B Hellmann; U Specks; N B Allen; J C Davis; R F Spiera; L H Calabrese; F M Wigley; N Maiden; R M Valente; J L Niles; K H Fye; J W McCune; E W St Clair; R A Luqmani
Journal:  Arthritis Rheum       Date:  2001-04

Review 2.  Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7.

Authors:  Peter A Merkel; Philip Seo; Peter Aries; Tuhina Neogi; Alexandra Villa-Forte; Maarten Boers; David Cuthbertson; David T Felson; Bernhard Hellmich; Gary S Hoffman; David R Jayne; Cees G M Kallenberg; Jeffrey Krischer; Alfred Mahr; Eric L Matteson; Ulrich Specks; Raashid Luqmani; John Stone
Journal:  J Rheumatol       Date:  2005-12       Impact factor: 4.666

3.  Development and validation of a disease extent index for Wegener's granulomatosis.

Authors:  K de Groot; W L Gross; K Herlyn; E Reinhold-Keller
Journal:  Clin Nephrol       Date:  2001-01       Impact factor: 0.975

4.  A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis.

Authors:  L Guillevin; J F Cordier; F Lhote; P Cohen; B Jarrousse; I Royer; P Lesavre; C Jacquot; P Bindi; P Bielefeld; J F Desson; F Détrée; A Dubois; E Hachulla; B Hoen; D Jacomy; C Seigneuric; D Lauque; M Stern; M Longy-Boursier
Journal:  Arthritis Rheum       Date:  1997-12

5.  Etanercept plus standard therapy for Wegener's granulomatosis.

Authors: 
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

6.  Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).

Authors:  Philip Seo; Yuan-I Min; Janet T Holbrook; Gary S Hoffman; Peter A Merkel; Robert Spiera; John C Davis; Steven R Ytterberg; E William St Clair; W Joseph McCune; Ulrich Specks; Nancy B Allen; Raashid A Luqmani; John H Stone
Journal:  Arthritis Rheum       Date:  2005-07

7.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

Authors:  David Jayne; Niels Rasmussen; Konrad Andrassy; Paul Bacon; Jan Willem Cohen Tervaert; Jolanta Dadoniené; Agneta Ekstrand; Gill Gaskin; Gina Gregorini; Kirsten de Groot; Wolfgang Gross; E Christiaan Hagen; Eduardo Mirapeix; Erna Pettersson; Carl Siegert; Alberto Sinico; Vladimir Tesar; Kerstin Westman; Charles Pusey
Journal:  N Engl J Med       Date:  2003-07-03       Impact factor: 91.245

8.  Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients.

Authors:  Loïc Guillevin; Pascal Cohen; Alfred Mahr; Jean-Pierre Arène; Luc Mouthon; Xavier Puéchal; Edouard Pertuiset; Brigitte Gilson; Mohamed Hamidou; Patricia Lanoux; Alain Bruet; Marc Ruivard; Philippe Vanhille; Jean-François Cordier
Journal:  Arthritis Rheum       Date:  2003-02-15

9.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

Authors:  R A Luqmani; P A Bacon; R J Moots; B A Janssen; A Pall; P Emery; C Savage; D Adu
Journal:  QJM       Date:  1994-11

10.  Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients.

Authors:  L Guillevin; F Lhote; M Gayraud; P Cohen; B Jarrousse; O Lortholary; N Thibult; P Casassus
Journal:  Medicine (Baltimore)       Date:  1996-01       Impact factor: 1.889

  10 in total
  20 in total

Review 1.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome.

Authors:  Raphaèle Seror; Philippe Ravaud; Simon J Bowman; Gabriel Baron; Athanasios Tzioufas; Elke Theander; Jacques-Eric Gottenberg; Hendrika Bootsma; Xavier Mariette; Claudio Vitali
Journal:  Ann Rheum Dis       Date:  2009-06-28       Impact factor: 19.103

3.  Mapping of the outcome measures in rheumatology core set for antineutrophil cytoplasmic antibody-associated vasculitis to the International Classification of Function, Disability and Health.

Authors:  Nataliya Milman; Annelies Boonen; Peter A Merkel; Peter Tugwell
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-02       Impact factor: 4.794

4.  Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis.

Authors:  Peter C Grayson; Paul A Monach; Christian Pagnoux; David Cuthbertson; Simon Carette; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Kathleen Maksimowicz-McKinnon; Philip Seo; Ulrich Specks; Steven R Ytterberg; Peter A Merkel
Journal:  Rheumatology (Oxford)       Date:  2014-11-17       Impact factor: 7.580

5.  Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.

Authors:  Marta Casal Moura; Maria V Irazabal; Alfonso Eirin; Ladan Zand; Sanjeev Sethi; Bijan J Borah; Jeffrey L Winters; James P Moriarty; Rodrigo Cartin-Ceba; Alvise Berti; Misbah Baqir; Gwen E Thompson; Ashima Makol; Kenneth J Warrington; Viengneesee Thao; Ulrich Specks; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2020-08-21       Impact factor: 10.121

Review 6.  [S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].

Authors:  Jan Henrik Schirmer; Peer M Aries; Kirsten de Groot; Bernhard Hellmich; Julia U Holle; Christian Kneitz; Ina Kötter; Peter Lamprecht; Ulf Müller-Ladner; Eva Reinhold-Keller; Christof Specker; Michael Zänker; Frank Moosig
Journal:  Z Rheumatol       Date:  2017-11       Impact factor: 1.372

7.  Rituximab for the treatment of Churg-Strauss syndrome with renal involvement.

Authors:  Rodrigo Cartin-Ceba; Karina A Keogh; Ulrich Specks; Sanjeev Sethi; Fernando C Fervenza
Journal:  Nephrol Dial Transplant       Date:  2011-02-16       Impact factor: 5.992

8.  Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement--a prospective, open-label pilot trial.

Authors:  Francisco Silva; Ulrich Specks; Sanjay Kalra; Marie C Hogan; Nelson Leung; Sanjeev Sethi; Fernando C Fervenza
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-21       Impact factor: 8.237

9.  Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9.

Authors:  Peter A Merkel; Karen Herlyn; Alfred D Mahr; Tuhina Neogi; Philip Seo; Michael Walsh; Maarten Boers; Raashid Luqmani
Journal:  J Rheumatol       Date:  2009-10       Impact factor: 4.666

10.  The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis.

Authors:  Tanaz A Kermani; David Cuthbertson; Simon Carette; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Kathleen McKinnon-Maksimowicz; Carol A McAlear; Paul A Monach; Philip Seo; Kenneth J Warrington; Steven R Ytterberg; Peter A Merkel; Eric L Matteson
Journal:  J Rheumatol       Date:  2016-04-01       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.